A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia
The goal of this study was to compare the consistency of three assays for the determination of the drug resistance of Mycobacterium tuberculosis (MTB) strains with various resistance profiles isolated from the Moscow region. A total of 144 MTB clinical isolates with a strong bias toward drug resista...
Saved in:
| Published in: | PloS one Vol. 11; no. 11; p. e0167093 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Public Library of Science
30-11-2016
Public Library of Science (PLoS) |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The goal of this study was to compare the consistency of three assays for the determination of the drug resistance of Mycobacterium tuberculosis (MTB) strains with various resistance profiles isolated from the Moscow region.
A total of 144 MTB clinical isolates with a strong bias toward drug resistance were examined using Bactec MGIT 960, Sensititre MycoTB, and a microarray-based molecular assay TB-TEST to detect substitutions in the rpoB, katG, inhA, ahpC, gyrA, gyrB, rrs, eis, and embB genes that are associated with resistance to rifampin, isoniazid, fluoroquinolones, second-line injectable drugs and ethambutol.
The average correlation for the identification of resistant and susceptible isolates using the three methods was approximately 94%. An association of mutations detected with variable resistance levels was shown. We propose a change in the breakpoint minimal inhibitory concentration for kanamycin to less than 5 μg/ml in the Sensititre MycoTB system. A pairwise comparison of the minimal inhibitory concentrations (MICs) of two different drugs revealed an increased correlation in the first-line drug group and a partial correlation in the second-line drug group, reflecting the history of the preferential simultaneous use of drugs from these groups. An increased correlation with the MICs was also observed for drugs sharing common resistance mechanisms.
The quantitative measures of phenotypic drug resistance produced by the Sensititre MycoTB and the timely detection of mutations using the TB-TEST assay provide guidance for clinicians for the choice of the appropriate drug regimen. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: DG and DZ are from a group of developers that invented the TB-TEST microarray assay and are the only authors of Russian patent #2562866, filed by the Engelhardt Institute of Molecular Biology (EIMB). Currently, the TB-TEST kit is produced and sold by the EIMB spin-off company Biochip-IMB, LLC. DG and DZ earned royalties from patent licensing (in 2015 these royalties comprised approximately $100 US dollars per person). DG and DZ are not employees of the Biochip-IMB company and have no direct commercial or financial relationship with this company. There are not any further patents, products in development or marketed products to declare. Therefore, we declare that this circumstance does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist. Conceptualization: EYN SGS. Data curation: EYN DVZ. Formal analysis: AAK KYG. Funding acquisition: DAG EMB. Investigation: AAK AII LYK KYG. Methodology: LYK MVM. Project administration: EMB VIL. Resources: VIL. Supervision: VIL EMB. Validation: AII MAK. Visualization: DVZ. Writing – original draft: EYN. Writing – review & editing: DVZ DAG. |
| ISSN: | 1932-6203 1932-6203 |
| DOI: | 10.1371/journal.pone.0167093 |